These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 20298204

  • 1. Drug targets for amyloidosis.
    Kolstoe SE, Wood SP.
    Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
    [Abstract] [Full Text] [Related]

  • 2. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS, Palaninathan SK, Sacchettini JC, Kelly JW.
    J Am Chem Soc; 2003 Nov 05; 125(44):13404-14. PubMed ID: 14583036
    [Abstract] [Full Text] [Related]

  • 4. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
    Lemstra AW, Eikelenboom P, Meijer EW, van Gool WA.
    Ned Tijdschr Geneeskd; 2002 Sep 14; 146(37):1720-3. PubMed ID: 12357871
    [Abstract] [Full Text] [Related]

  • 5. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
    Julius RL, Hawthorne MF.
    Drug News Perspect; 2008 Jun 14; 21(5):258-66. PubMed ID: 18596990
    [Abstract] [Full Text] [Related]

  • 6. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
    Arbustini E, Gavazzi A, Merlini G.
    Ital Heart J Suppl; 2002 Jun 14; 3(6):590-7. PubMed ID: 12116807
    [Abstract] [Full Text] [Related]

  • 7. Amyloid diseases: small drugs lead the attack.
    Iversen L.
    Nature; 2002 May 16; 417(6886):231-3. PubMed ID: 12015581
    [No Abstract] [Full Text] [Related]

  • 8. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC.
    Ann N Y Acad Sci; 2005 Dec 16; 1066():181-221. PubMed ID: 16533927
    [Abstract] [Full Text] [Related]

  • 9. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
    Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW.
    Acc Chem Res; 2005 Dec 16; 38(12):911-21. PubMed ID: 16359163
    [Abstract] [Full Text] [Related]

  • 10. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
    Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB.
    Br J Haematol; 2010 Mar 16; 148(5):760-7. PubMed ID: 20064157
    [Abstract] [Full Text] [Related]

  • 11. Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin.
    Almeida MR, Saraiva MJ.
    FEBS Lett; 2012 Aug 31; 586(18):2891-6. PubMed ID: 22819819
    [Abstract] [Full Text] [Related]

  • 12. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
    Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW.
    Biochemistry; 2003 Jun 10; 42(22):6656-63. PubMed ID: 12779320
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB.
    N Engl J Med; 2015 Sep 17; 373(12):1106-14. PubMed ID: 26176329
    [Abstract] [Full Text] [Related]

  • 14. [Amyloidosis: a model of misfolded protein disorder].
    Grateau G, Verine J, Delpech M, Ries M.
    Med Sci (Paris); 2005 Sep 17; 21(6-7):627-33. PubMed ID: 15985206
    [Abstract] [Full Text] [Related]

  • 15. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M, Andrisano V.
    Chembiochem; 2010 May 17; 11(8):1018-35. PubMed ID: 20401887
    [Abstract] [Full Text] [Related]

  • 16. Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options.
    Tillement JP, Lecanu L, Papadopoulos V.
    Pharmacology; 2010 May 17; 85(1):1-17. PubMed ID: 19923873
    [Abstract] [Full Text] [Related]

  • 17. Amyloidosis: a clinico-pathophysiological synopsis.
    Hirschfield GM.
    Semin Cell Dev Biol; 2004 Feb 17; 15(1):39-44. PubMed ID: 15036205
    [Abstract] [Full Text] [Related]

  • 18. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
    Pepys MB.
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb 28; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry.
    Kingsbury JS, Théberge R, Karbassi JA, Lim A, Costello CE, Connors LH.
    Anal Chem; 2007 Mar 01; 79(5):1990-8. PubMed ID: 17261023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.